Blaze Bioscience Announces Trial in Progress Presentation at ASCO 2016 Annual Meeting
Ongoing clinical study of Tumor Paint BLZ-100 in pediatric brain cancer patients highlighted

SEATTLE, WA – May 31, 2016 – Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2016 Annual Meeting, taking place in Chicago, IL on June 3-7, 2016.

The poster presentation, titled “Phase 1 Dose Escalation and Expansion Safety Study of BLZ-100 in Pediatric Subjects with Primary Central Nervous System Tumors,” will highlight the company’s first study in the pediatric population.

Details of the poster presentation are as follows:
**Trials in Progress Presentation – Pediatric Oncology Session**
Date: Monday, June 6, 2016
Time: 8:00 AM – 11:30 AM CDT
Location: Hall A
Poster Number: 274b
Abstract Number: TPS10584

**About BLZ-100**
BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is an investigational agent currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, and colorectal cancer. More details about on-going trials are available at [www.blazebioscience.com](http://www.blazebioscience.com) or [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**About Blaze Bioscience**
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former member of the executive management team at ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide-based therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products have the potential to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop products based on knottin peptides as part of the Optides platform. This program extends the expertise gained in
developing the Tumor Paint platform to optimize knottin peptides for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

# # #

Contact

Media-
Lauren Nelson
Blaze Bioscience, Inc.
(206) 535-8144
lauren.nelson@blazebioscience.com

Investor Relations-
Susan Specht Oram
SOS Communications LLC
(360) 535-3035
spechtoram@gmail.com